SCHEMBL6394209

SCHEMBL6394209

O=C(NCCC1SC(NC2CCCCCCC2)=NC1=O)c1ccccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPC1 O15118 4/20 0.41
HPGD P15428 3/20 0.40
P2RX7 Q99572 1/20 0.40
USP2 O75604 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM3 P20309 1/20 0.40
NAMPT P43490 1/20 0.39
TYRO3 Q06418 1/20 0.39
CTSL P07711 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6393301 1.00 RAB9A (0.43) RAB9ATDP1NPC1HPGDP2RX7
SCHEMBL6390207 1.00 RAB9A (0.43) RAB9ATDP1NPC1HPGDP2RX7
SCHEMBL6387585 0.88 POLB (0.44) RAB9ATDP1NPC1HPGDP2RX7
SCHEMBL6392636 0.88 POLB (0.44) RAB9ATDP1NPC1HPGDP2RX7
SCHEMBL6505267 0.88 ATM (0.41) RAB9ANPC1NAMPTCTSLCTSS
SCHEMBL6505517 0.87 RAB9A (0.41) RAB9AHPGDPOLBSMN1; SMN2ALDH1A1
SCHEMBL6393708 0.86 NPC1 (0.41) RAB9ANPC1HPGDP2RX7CTSS
SCHEMBL6387573 0.85 SMN1; SMN2 (0.44) RAB9ANPC1HPGDP2RX7POLB
SCHEMBL6504984 0.85 SMN1; SMN2 (0.44) RAB9ANPC1HPGDP2RX7POLB
SCHEMBL6388874 0.85 SMN1; SMN2 (0.44) RAB9ANPC1HPGDP2RX7POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US claimed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO claimed
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239853-A1 New compounds HSD11B1, CYP11B1, HSD3B1 RAB9A 2649/4885TDP1 804/4885NPC1 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.